Kimpel CC, Myer EA, Cupples A, Roman Jones J, Seidler KJ, Rick CK, Brown R, Rawlins C, Hadler R, Tsivitse E, Lawlor MAC, Ratcliff A, Holt NR, Callaway-Lane C, Godwin K, Ecker AH. Identifying barriers and facilitators to veterans affairs whole health integration using the updated consolidated framework for implementation research. J Healthc Qual. 2024 May;43(6):137-49. doi: 10.1097/JHQ.0000000000000419
MacLeod S, Musich S, Hawkins K, Schwebke K. Highlighting a common quality of care delivery problem: overuse of low-value healthcare services. J Healthc Qual. 2018 Jul;40(4):201-8. doi: 10.1097/JHQ.0000000000000095
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Psychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; September 19, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 52(S47):453.
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Pysychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; November 2, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 2017 Sep 19; 52(S47):S453. doi: 10.1002/ppul.23840
Santanello N, Norquist J, Nelsen L, Williams V, Hill CD, Bisgaard H. Validation of a pediatric caregiver diary to measure symptoms of postacute respiratory syncytial virus bronchiolitis. Pediatr Pulmonol. 2005 Jul 1;40(1):31-8.
Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, Humphries SE, Talmud PJ. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92(9):969-75.
Enger C, Rothman KJ, Kylstra JW. Mortality rates during two years of treatment with intermittent inhaled tobramycin (TOBI) in cystic fibrosis. Pediatr Pulmonol. 1999 Sep 22;28(Suppl 19):339-40.